Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of contemporary insights in health sciences

Enumeration of CD3ˉCD56⁺CD16⁺ and NKG2D⁺ Natural Killer Cells in Breast Cancer Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNoreen MajeedMMMuhammad Usman MinhasRTRomeeza Tahir

Discussion

Loading...

Member takes

Overview

Prospective case control study identified changes in NK cell subsets and NKG2D levels in breast cancer patients, suggesting immune modulation.

Key Points

  • Breast cancer patients exhibited changes in NK cell subsets and decreased NKG2D expression, indicating potential immune evasion.
  • The mean NK cell count was higher in patients (9.5) compared to controls (8.5), but not statistically significant (p = 0.39).
  • NKG2D expression was significantly lower in breast cancer patients (52) compared to controls (67), indicating altered immune response (p = 0.005).
  • Assessment was performed on 40 breast cancer patients and 40 healthy controls, highlighting differences in immune cell populations.

Cite This Study

Majeed et al. (2024) studied this question.

synapsesocial.com/papers/68c1e08354b1d3bfb60fd8a5https://doi.org/10.69591/jcihs.2.2.3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer2024 · 10 citations
  2. 2Preferential apoptosis of CD56<sup>dim</sup> natural killer cell subset in patients with cancer2002 · 166 citations
  3. 3Accumulation of CD56<sup>+</sup> CD16<sup>-</sup> Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer2024 · 1 citations
  4. 4Spatial distribution and functional heterogeneity of CD56bright and CD56dim natural killer cells and the effects on the immune microenvironment in ovarian cancer.2026
  5. 5Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients2026